Testosterone and aging: the decline is not one fixed percentage for every man
Longitudinal studies show that age, obesity, illness, medicines, and measurement conditions all shape testosterone trends. Here is a more accurate guide.

Average testosterone levels often decline across adulthood, but an individual’s trajectory is not predetermined. Health changes and measurement conditions contribute, and age alone does not diagnose hypogonadism.
An average trend is not a personal forecast
Population studies often show lower average testosterone in older groups, which is commonly summarized as a fixed annual decline. That shorthand hides wide variation between individuals. It also mixes cross-sectional comparisons—different people measured at one time—with longitudinal observations of the same people over years.
A number quoted from one cohort depends on who enrolled, who returned for follow-up, the assay used, the time of collection, and how researchers handled obesity, illness, and medication use. It can describe a group but cannot predict the next laboratory result for a particular man.

Longitudinal cohorts tell different parts of the story
The Massachusetts Male Aging Study followed men who were 40 to 70 at enrollment. Its longitudinal estimates showed declines in total and bioavailable testosterone, with steeper changes than some cross-sectional estimates. The investigators noted that incident poor health could help explain why within-person decline looked larger than comparisons across age groups.
A later five-year study of community-dwelling men reached a more conditional conclusion. Testosterone changes were associated with obesity, smoking behavior, depression, relationship status, and newly developed chronic disease. The authors wrote that age-related decline was not inevitable and was largely explained by changes in health and behavior.
A newer analysis emphasizes comorbidity
In a 2023 analysis from the Baltimore Longitudinal Study of Aging, researchers repeatedly assessed 625 men. After accounting for comorbidities, age was not significantly associated with declining total testosterone. Anemia, diabetes, heart failure, obesity, peripheral artery disease, and stroke were associated with lower levels.
That result does not prove that age is irrelevant or that treating a comorbidity will restore a specific hormone level. It shows why a universal “one percent per year” claim is too neat. Age travels with changes in body composition, health, sleep, and medicines, and statistical models make different choices about those relationships.
Symptoms and repeat measurements still define the clinical question
The Endocrine Society’s current position is that diagnosis requires symptoms consistent with testosterone deficiency plus consistently low, accurately measured blood testosterone. It does not define normal aging itself as a disease and does not support population screening of asymptomatic men.
Common concerns such as lower energy, mood changes, and reduced exercise capacity have many possible causes. More specific sexual, reproductive, hematologic, or bone findings may raise concern, but no symptom makes the diagnosis alone. Two early-morning fasting measurements and evaluation for reversible or structural causes provide a stronger foundation than an age-adjusted marketing quiz.

Focus on health rather than chasing a youthful number
Addressing obesity, diabetes, sleep disorders, excessive alcohol use, inactivity, depression, and medication effects can improve health whether or not testosterone rises. These are not guaranteed hormone interventions. They are clinically relevant factors that deserve attention before a low result is attributed to a birthday.
Testosterone therapy may benefit appropriately diagnosed men, but it also requires a discussion of fertility, contraindications, monitoring, and unresolved long-term questions. The more accurate aging message is neither “decline is inevitable” nor “everyone can reverse it.” Individual trajectories vary, and good decisions begin with symptoms, standardized testing, and the broader health picture.
What a useful baseline can and cannot do
Testing a healthy person simply to establish a youthful benchmark is not the same as evaluating symptoms, and endocrine guidance does not recommend general population screening. A baseline obtained during illness, calorie restriction, poor sleep, or late in the day may create a misleading anchor that follows the person for years.
When testing is clinically indicated, record the conditions and repeat an unexpectedly low value. Comparisons are most useful when collection timing, laboratory method, and health context are similar. Even then, the aim is not to preserve a number from age 30 forever; it is to identify a consistent deficiency and its cause when symptoms support investigation.
A trend also should not be read without symptoms. Movement from one normal value to another may have little clinical meaning, while a consistently low result with specific symptoms deserves attention. Decisions should follow the full pattern, not the percentage change alone.
Sources & further reading
- Age trends in serum testosterone: longitudinal results from the Massachusetts Male Aging Study ↗
- Longitudinal changes in testosterone over five years in community-dwelling men ↗
- Association between comorbidities and longitudinal changes in total testosterone ↗
- Endocrine Society statement on testosterone replacement therapy ↗
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.